Reshaping the HIV treatment and prevention landscape
Maximising
high-potential
Specialty
Medicines
Double digit % growth CAGR 2021-26
Infectious diseases: industry leader with broadest pipeline
HIV: pioneering innovation for treatment and prevention
Oncology: leadership in next-gen IO and synthetic lethality
Immunology/Respiratory: genetically-validated immune driven targets
Opportunity driven: create future therapy areas of focus
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of
preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life
Cycle Innovation (LCI) launched from 2021 onwards.
10 immuno-oncology
83View entire presentation